Home > Insider Trading > Filing (0001104659-24-084334)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1137883	Brainstorm Cell Therapeutics Inc.	BCLI	Biological Products, (No Disgnostic Substances) (2836)	207273918

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1406302	Chaim Lebovits	C/O Brainstorm Cell Therapeutics Inc. 1325 Avenue Of The Americas 28Th Floor New York NY 10019	President & Ceo	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-04-17	130,000	$0.55	728,493	No	4	P	Direct
Common Stock	Acquisiton	2024-04-18	115,072	$0.53	843,565	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	P	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	2,000,847	Indirect	See footnote

Footnotes

On April 19, 2024, the Reporting Person filed a Form 4 which inadvertently included incorrect transaction codes due to an administrative error. This amendment is being filed solely to reflect the correct transaction code 'P' instead of transaction code 'A'.
The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.5392 to $0.555, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote (2) to this Form 4.
The price reported in Column 4 is a weighted average price. These securities were purchased in multiple transactions at prices ranging from $0.4936 to $0.59, inclusive. The ReportingPerson undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number ofsecurities purchased at each separate price within the range set forth in this footnote (3) to this Form 4.
Includes (i) 1,933,794 shares of Common Stock owned by ACCBT Corp. and (ii) 67,053 shares of Common Stock owned by ACC International Holdings Ltd. Reporting Person may bedeemed the beneficial owner of these shares.